keyword
MENU ▼
Read by QxMD icon Read
search

Parkinson hallucination

keyword
https://www.readbyqxmd.com/read/28630780/a-randomized-controlled-trial-of-chinese-medicine-on-nonmotor-symptoms-in-parkinson-s-disease
#1
Ka-Kit Chua, Adrian Wong, Kam-Wa Chan, Yin-Kei Lau, Zhao-Xiang Bian, Jia-Hong Lu, Liang-Feng Liu, Lei-Lei Chen, Ka-Ho Chan, Kim-Pong Tse, Anne Chan, Ju-Xian Song, Justin Wu, Li-Xing Zhu, Vincent Mok, Min Li
Nonmotor symptoms (NMS) of Parkinson's disease (PD) have devastating impacts on both patients and their caregivers. Jiawei-Liujunzi Tang (JLT) has been used to treat some NMS of PD based on the Chinese medicine theory since Qing dynasty. Here we report a double-blind, randomized, placebo-controlled, add-on clinical trial aiming at evaluating the efficacy and safety of the JLT in treating NMS in PD patients. We randomly assigned 111 patients with idiopathic PD to receive either JLT or placebo for 32 weeks. Outcome measures were baseline to week 32 changes in Movement Disorder Society-Sponsored Revision of Unified PD Rating Scale (MDS-UPDRS) Parts I-IV and in NMS assessment scale for PD (NMSS)...
2017: Parkinson's Disease
https://www.readbyqxmd.com/read/28611642/a-case-report-of-severe-delirium-after-amantadine-withdrawal
#2
Franz Marxreiter, Jürgen Winkler, Martin Uhl, Dominik Madžar
Amantadine is frequently used in addition to dopaminergic substances like dopamine agonists or L-Dopa in advanced Parkinson disease (PD). However, adverse effects like hallucinations limit its use. PD patients developing severe psychotic symptoms upon treatment with either dopaminergic substances and/or amantadine need to stop intake of any psychotropic substance. Here, we report the case of a 71-year-old PD patient without previously known cognitive impairment. He presented with drug-induced psychotic symptoms due to changes in his therapeutic regimen (increase in COMT inhibitors, newly introduced MAO B inhibitors)...
January 2017: Case Reports in Neurology
https://www.readbyqxmd.com/read/28604926/ads-5102-amantadine-extended-release-capsules-for-levodopa-induced-dyskinesia-in-parkinson-disease-ease-lid-study-a-randomized-clinical-trial
#3
Rajesh Pahwa, Caroline M Tanner, Robert A Hauser, Stuart H Isaacson, Paul A Nausieda, Daniel D Truong, Pinky Agarwal, Keith L Hull, Kelly E Lyons, Reed Johnson, Mary Jean Stempien
Importance: Medical treatment of levodopa-induced dyskinesia (LID) in Parkinson disease (PD) is an unmet need. Objective: To evaluate the efficacy and safety of ADS-5102 (amantadine) extended-release 274-mg capsules for treatment of LID in patients with PD. Design, Setting, and Participants: A randomized, double-blind, placebo-controlled clinical trial was conducted between May 7, 2014, and July 22, 2015, at 44 North American sites among patients with PD treated with levodopa who experienced at least 1 hour of troublesome dyskinesia per day with at least mild functional impact...
June 12, 2017: JAMA Neurology
https://www.readbyqxmd.com/read/28600444/deconstructing-psychosis-and-misperception-symptoms-in-parkinson-s-disease
#4
Yoshiyuki Nishio, Kayoko Yokoi, Makoto Uchiyama, Yasuyuki Mamiya, Hiroyuki Watanabe, Miyeong Gang, Toru Baba, Atsushi Takeda, Kazumi Hirayama, Etsuro Mori
OBJECTIVE: Patients with Lewy body disease develop a variety of psychotic and misperception symptoms, including visual hallucinations and delusions, as well as 'minor hallucinations', that is, a sense of presence, passage hallucinations and visual illusions. Although these symptoms have been suggested to have common underlying mechanisms, the commonalities and differences among them have not been systematically investigated at the neural level. METHODS: Sixty-seven patients with Parkinson's disease underwent neuropsychological and behavioural assessments, volumetric MRI and 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET)...
June 9, 2017: Journal of Neurology, Neurosurgery, and Psychiatry
https://www.readbyqxmd.com/read/28579723/pimavanserin-nuplazid-a-treatment-for-hallucinations-and-delusions-associated-with-parkinson-s-disease
#5
Martin Paspe Cruz
Pimavanserin (Nuplazid) for the treatment of hallucinations and delusions associated with Parkinson's disease.
June 2017: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/28578818/clinical-milestones-in-parkinson-s-disease-a-7-year-population-based-incident-cohort-study
#6
Anders Bjornestad, Kenn Freddy Pedersen, Ole-Bjorn Tysnes, Guido Alves
INTRODUCTION: Clinical staging of Parkinson's disease (PD) is important for patient management and prognosis. The non-motor and functional features visual hallucinations, recurrent falls, dementia and nursing home placement are currently not included in clinical staging schemes, but have been suggested as clinical milestones with important prognostic implications in advanced PD. In this study, we sought to evaluate the potential of these four milestone events for clinical staging and prognosis during the early years of the disease...
May 29, 2017: Parkinsonism & related Disorders
https://www.readbyqxmd.com/read/28566609/progressive-b%C3%A3-lint-s-syndrome-in-a-patient-demonstrating-dementia-with-lewy-bodies
#7
Yasuhisa Sakurai, Yoshifumi Nakashima
We herein report a 65-year-old man demonstrating dementia with Lewy bodies who first presented with Bálint's syndrome. Two years later, a mild cognitive impairment was noted. From three years after onset, he developed progressive parkinsonism, visual hallucination, and autonomic dysfunction, in line with the deterioration of the cognitive function. Single photon emission computed tomography with a (99m)Tc-ethylcysteinate dimer performed two years after onset revealed hypoperfusion in the restricted area of the bilateral superior parietal lobule, which extended to the lateral occipital cortices within two years...
2017: Internal Medicine
https://www.readbyqxmd.com/read/28553118/psychosis-in-parkinsonism-an-unorthodox-approach
#8
REVIEW
Marco Onofrj, Danilo Carrozzino, Aurelio D'Amico, Roberta Di Giacomo, Stefano Delli Pizzi, Astrid Thomas, Valeria Onofrj, John-Paul Taylor, Laura Bonanni
Psychosis in Parkinson's disease (PD) is currently considered as the occurrence of hallucinations and delusions. The historical meaning of the term psychosis was, however, broader, encompassing a disorganization of both consciousness and personality, including behavior abnormalities, such as impulsive overactivity and catatonia, in complete definitions by the International Classification of Diseases-10 (ICD-10) and the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). Our review is aimed at reminding that complex psychotic symptoms, including impulsive overactivity and somatoform disorders (the last being a recent controversial entity in PD), were carefully described in postencephalitic parkinsonism (PEP), many decades before dopaminergic treatment era, and are now described in other parkinsonisms than PD...
2017: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/28547577/pramipexole-overdose-associated-with-visual-hallucinations-agitation-and-myoclonus
#9
Adeline Cardon-Dunbar, Tom Robertson, Michael S Roberts, Geoffrey K Isbister
INTRODUCTION: Pramipexole is a dopamine D2 receptor agonist used to treat idiopathic Parkinson's disease and primary restless legs syndrome. There is limited information on pramipexole overdose. CASE REPORT: A 59-year-old male ingested 3 mg pramipexole, 2250 mg venlafaxine, 360 mg mirtazapine, with suicidal intent. He presented alert, had normal vital observations and normal pupillary reflexes. He was mildly agitated, reported visual hallucinations and was given 5 mg diazepam...
May 25, 2017: Journal of Medical Toxicology: Official Journal of the American College of Medical Toxicology
https://www.readbyqxmd.com/read/28493654/the-us-food-and-drug-administration-s-perspective-on-the-new-antipsychotic-pimavanserin
#10
Mitchell V Mathis, Brendan M Muoio, Paul Andreason, Amy M Avila, Tiffany Farchione, Aisar Atrakchi, Robert J Temple
OBJECTIVE: To summarize the US Food and Drug Administration's (FDA's) review of the safety and effectiveness for pimavanserin, an atypical antipsychotic, for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. We describe the regulatory and clinical issues important to the FDA's approval of this New Drug Application, with special focus on the risk-benefit balance. We also describe a new labeling feature that presents additional efficacy data to clinicians...
May 9, 2017: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/28435846/psychometric-properties-and-characteristics-of-the-north-east-visual-hallucinations-interview-in-parkinson-s-disease
#11
Kelsey A Holiday, Eva Pirogovsky-Turk, Vanessa L Malcarne, J Vincent Filoteo, Irene Litvan, Stephanie L Lessig, David Song, Dawn M Schiehser
BACKGROUND: Visual Hallucinations (VH) are a common symptom experienced by individuals with Parkinson's disease (PD); however, a validated measure of VH has yet to be established for this population. The North-East Visual Hallucinations Interview (NEVHI), a promising VH measure, has not been well validated in PD. The aim of this study was to evaluate the convergent and discriminant validity of the NEVHI as well as the proportional identification and characteristics of VH in PD. METHODS: One hundred seventeen individuals with PD completed the NEVHI as well as evaluations of psychological, cognitive, motor, and visual functioning as measures of convergent and divergent validity...
March 16, 2017: Movement Disorders Clinical Practice
https://www.readbyqxmd.com/read/28434243/-clinical-and-neuropathological-characteristics-of-dementia-with-lewy-bodies
#12
János Bencze, Viktória Simon, Erika Bereczki, Réka Majer, Gréta Varkoly, Balázs Murnyák, János Kálmán, Tibor Hortobágyi
Dementia with Lewy bodies (DLB) is the second most common neurodegenerative dementia. The accurate diagnosis is often possible only by neuropathological examination. The morphologic hallmarks are the presence of α-synuclein-rich Lewy bodies and Lewy neurites, identical to those seen in Parkinson's disease (PD) and Parkinson's disease dementia (PDD). Neurotransmitter deficits, synaptic and ubiquitin-proteasome system (UPS) dysfunction play major role in the pathomechanism. Characteristic symptoms are cognitive fluctuation, parkinsonism and visual hallucinations...
April 2017: Orvosi Hetilap
https://www.readbyqxmd.com/read/28385039/evidence-based-review-of-pharmacotherapy-used-for-parkinson-s-disease-psychosis
#13
Kyle John Wilby, Eric G Johnson, Hannah E Johnson, Mary H H Ensom
OBJECTIVE: To summarize and evaluate the existing literature regarding medications to treat Parkinson's disease (PD) psychosis. DATA SOURCES: MEDLINE (1946 to March 2017), EMBASE (1980 to March 2017), CINAHL (1982 to March 2017), and PsychInfo (1887 to March 2017) were searched using the following terms: Parkinson disease, Parkinson's disease, psychotic disorders, psychosis, delusions, and hallucinations. STUDY SELECTION AND DATA EXTRACTION: The search was limited to randomized controlled trials (RCTs) reporting human outcomes...
April 1, 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/28375643/pimavanserin
#14
Kevin M Bozymski, Denise K Lowe, Kiersten M Pasternak, Travis L Gatesman, Ericka L Crouse
OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, safety, and place in therapy of pimavanserin for the treatment of hallucinations and delusions of Parkinson's disease psychosis (PDP). DATA SOURCES: A comprehensive PubMed search (1966 to January 2017) was conducted using the search terms Parkinson's disease psychosis, hallucinations, delusions, pimavanserin, and ACP-103. Additional data were obtained from references of identified articles, governmental sources, manufacturer product labeling and website, and Clinicaltrials...
February 1, 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/28364292/continuous-subcutaneous-apomorphine-infusion-in-advanced-parkinson-s-disease-10-year-experience-with-230-patients
#15
Ángel Sesar, Gustavo Fernández-Pajarín, Begoña Ares, María Teresa Rivas, Alfonso Castro
Continuous apomorphine infusion (APO) is one of the treatments available for advanced Parkinson disease (PD). Over 10 years, we have treated 230 patients with APO. Mean age was 66.8 and average evolution time at APO onset was 13.0 years. Mean duration of the treatment was 26.3 months. As of June 2016, 93 remained on the medication (active group), while 137 had stopped. This active group had mean age 67.3 at recruitment and mean evolution 14.2 years. The main indication for APO was lack of deep brain stimulation criteria (DBS)...
March 31, 2017: Journal of Neurology
https://www.readbyqxmd.com/read/28361209/correlation-between-clinical-symptoms-and-striatal-dat-uptake-in-patients-with-dlb
#16
Soichiro Shimizu, Disuke Hirose, Nayuta Namioka, Hidekazu Kanetaka, Kentaro Hirao, Hirokuni Hatanaka, Naoto Takenoshita, Yoshitsugu Kaneko, Yusuke Ogawa, Takahiko Umahara, Hirofumi Sakurai, Haruo Hanyu
OBJECTIVE: It is widely known that there is low striatal (123)I-FP-CIT dopamine transporter-single photon emission tomography (DAT-SPECT) uptake in patients with dementia with Lewy bodies (DLB). We assessed the correlation between symptom and regional low DAT uptake in the striatum. METHODS: Patients with Alzheimer's disease (AD) (n = 95) and patients with DLB (n = 133) who underwent DAT-SPECT were enrolled. We examined the correlation between symptoms [cognitive function decline, fluctuations, visual hallucinations, parkinsonism, and REM sleep behavior disorder (RBD)] and regional striatal DAT uptake in the patients with DLB...
June 2017: Annals of Nuclear Medicine
https://www.readbyqxmd.com/read/28331324/update-on-the-treatment-of-parkinson-s-disease-psychosis-role-of-pimavanserin
#17
REVIEW
Brianna L Combs, Arthur G Cox
Parkinson's disease (PD) has a prevalence of nearly 1 million people in the USA, with increasing incidence in the elderly population. Generally, the age of presentation is between 55 and 65 years, with the likelihood of diagnosis increasing as patients reach the age of 80 years or above. Some of the common treatments for PD increase dopamine levels in the brain. Dopaminergic therapy helps to improve motor and non-motor symptoms, but it is not without risks. Dopaminergic therapy can cause confusion, delirium, and psychotic-like behavior...
2017: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/28320195/combined-use-of-dopamine-transporter-imaging-dat-spect-and-123-i-metaiodobenzylguanidine-mibg-myocardial-scintigraphy-for-diagnosing-parkinson-s-disease
#18
Fumihito Yoshii, Masafuchi Ryo, Yasuhiko Baba, Takashi Koide, Jun Hashimoto
BACKGROUND: To examine whether combined use of (123)I-FP-CIT dopamine transporter single photon emission computed tomography (DAT-SPECT) and (123)I-MIBG myocardial scintigraphy (MIBG) is superior to either modality alone for diagnosing Parkinson's disease (PD). METHODS: Patients with probable PD (n=120) who underwent both DAT-SPECT and MIBG myocardial scintigraphy within short intervals were enrolled. Specific binding ratio (SBR) of DAT-SPECT images and heart-to-mediastinum (H/M) ratio of MIBG images were used as quantitative measures...
April 15, 2017: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/28315846/risk-factors-for-early-psychosis-in-pd-insights-from-the-parkinson-s-progression-markers-initiative
#19
MULTICENTER STUDY
Dominic H Ffytche, Joana B Pereira, Clive Ballard, K Ray Chaudhuri, Daniel Weintraub, Dag Aarsland
BACKGROUND: Parkinson's Disease (PD) psychosis refers to the spectrum of illusions, formed hallucinations and delusions that occur in PD. Visual hallucinations and illusions are thought to be caused by specific cognitive and higher visual function deficits and patients who develop such symptoms early in the disease course have greater rates of cognitive decline and progression to dementia. To date, no studies have investigated whether such deficits are found prior to the onset of PD psychosis...
April 2017: Journal of Neurology, Neurosurgery, and Psychiatry
https://www.readbyqxmd.com/read/28284903/ocular-and-visual-disorders-in-parkinson-s-disease-common-but-frequently-overlooked
#20
REVIEW
Merel S Ekker, Sabine Janssen, Klaus Seppi, Werner Poewe, Nienke M de Vries, Thomas Theelen, Jorik Nonnekes, Bastiaan R Bloem
Patients with Parkinson's disease (PD) often compensate for their motor deficits by guiding their movements visually. A wide range of ocular and visual disorders threatens the patients' ability to benefit optimally from visual feedback. These disorders are common in patients with PD, yet they have received little attention in both research and clinical practice, leading to unnecessary - but possibly treatable - disability. Based on a literature search covering 50 years, we review the range of ocular and visual disorders in patients with PD, and classify these according to anatomical structures of the visual pathway...
February 21, 2017: Parkinsonism & related Disorders
keyword
keyword
48244
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"